AIDS_2026_ OAB1406LB

Title: Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-1 Phase 3 Trial

Author: Jürgen K Rockstroh

Oral Presentation

Graphical Summary

For information related to the ISLEND-2 study, please see oral OAX1106LB

Email Presentation

Share this information

Enter the information below to send this data to a friend or collegue.